Ed is the General Manager for the US Orphan Disease Rx business unit at Biocodex, Inc. Ed has 30 years of pharmaceutical experience including 20 years in Orphan Disease.
As the General Manager, Ed is responsible for overseeing daily operations of the business unit and ensuring the creation and implementation of strategies designed to grow the business while supporting the healthcare providers and patient communities.
Prior to Biocodex, Ed has led and been a part of teams designed to build, launch, and grow specialty medications in the oncology market.
Ed holds a bachelor’s degree in Marketing from The University of Maryland, College Park
Chief Compliance Officer
Scott is Head of Pharmaceutical Affairs and Chief Compliance Officer for the Rx US business unit at Biocodex, Inc. He joined Biocodex in 2019 and has brought 28 years of pharmaceutical and biotech industry experience across more than 22 disease states and 16 product launches.
Scott is responsible for oversight of Compliance, Regulatory, and Pharmacovigilance.
Prior to Biocodex, Scott spent the first 14 years of his career at Boehringer Ingelheim Pharmaceuticals in both sales and managed markets leadership roles. He has since had roles of increasing responsibility at Salix Pharmaceuticals, MiddleBrook Pharmaceuticals, Avanir Pharmaceutical, and Scilex Pharmaceuticals. During his career he also held positions in compliance with oversight of clinical, medical affairs, and commercial.
Scott holds a Bachelor of Science in Marketing from San Diego State University, Certification in Healthcare Compliance from Seton Hall University School of Law, and is a Certified Compliance and Ethics Professional (CCEP).
Want to know more?
With global headquarters in France, Biocodex has expanded its geographic footprint over the past 10 years and today operates through 20 affiliates and long-term partnerships in other countries. Through this international network, Biocodex offers health solutions to patients in more than 120 countries.
Biocodex develops, manufactures and distributes world-class pharmaceutical products and health solutions for patients in more than 120 countries. Focusing on three main pillars (microbiota mission, orphan drugs and women’s health), we combine in house R&D and scientific partnerships, production expertise, and investments in start-ups to remain at the forefront of innovation and quality.
Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology, featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota.